BACKGROUND: There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM). ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma. METHODS: A parallel phase II trial was conducted in patients with unresectable stage IV melanoma who were either chemotherapy naive (CN) or previously treated (PT). The treatment regimen consisted of ABI-007 (100 mg/m(2) ) and carboplatin area under the curve (AUC2) administered on days 1, 8, and 15 every 28 days. The primary aim of this study was objective response rate (RECIST). RESULTS: Seventy-six patients (41 CN and 35 PT) were enrolled between November 2006 and July 2007. Three patients withdrew consent prior to starting treatment. The median number of treatment cycles was 4. There were 10 (25.6%) responses (1 complete response [CR] and 9 partial responses [PRs]) in the CN cohort (90% CI, 16.7%-42.3%) and 3 (8.8%) responses (3 PRs) in the PT cohort (90% CI, 2.5%-21.3%). Median progression-free survival was 4.5 months in the CN cohort and 4.1 months in the PT cohort. Median overall survival (OS) was 11.1 months in the CN group and 10.9 months in the PT group. Severe toxicities in both groups (Common Terminology Criteria for Adverse Effects v.3.0 ≥grade 3) included neutropenia, thrombocytopenia, neurosensory problems, fatigue, nausea, and vomiting. CONCLUSIONS: The weekly combination of ABI-007 and carboplatin appears to be moderately well tolerated, with promising clinical activity as therapy in patients who are chemotherapy naive and with modest antitumor activity in those previously treated.
BACKGROUND: There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM). ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma. METHODS: A parallel phase II trial was conducted in patients with unresectable stage IV melanoma who were either chemotherapy naive (CN) or previously treated (PT). The treatment regimen consisted of ABI-007 (100 mg/m(2) ) and carboplatin area under the curve (AUC2) administered on days 1, 8, and 15 every 28 days. The primary aim of this study was objective response rate (RECIST). RESULTS: Seventy-six patients (41 CN and 35 PT) were enrolled between November 2006 and July 2007. Three patients withdrew consent prior to starting treatment. The median number of treatment cycles was 4. There were 10 (25.6%) responses (1 complete response [CR] and 9 partial responses [PRs]) in the CN cohort (90% CI, 16.7%-42.3%) and 3 (8.8%) responses (3 PRs) in the PT cohort (90% CI, 2.5%-21.3%). Median progression-free survival was 4.5 months in the CN cohort and 4.1 months in the PT cohort. Median overall survival (OS) was 11.1 months in the CN group and 10.9 months in the PT group. Severe toxicities in both groups (Common Terminology Criteria for Adverse Effects v.3.0 ≥grade 3) included neutropenia, thrombocytopenia, neurosensory problems, fatigue, nausea, and vomiting. CONCLUSIONS: The weekly combination of ABI-007 and carboplatin appears to be moderately well tolerated, with promising clinical activity as therapy in patients who are chemotherapy naive and with modest antitumor activity in those previously treated.
Authors: Ravi D Rao; Shernan G Holtan; James N Ingle; Gary A Croghan; Lisa A Kottschade; Edward T Creagan; Judith S Kaur; Henry C Pitot; Svetomir N Markovic Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Kevin B Kim; Jeffrey A Sosman; John P Fruehauf; Gerald P Linette; Svetomir N Markovic; David F McDermott; Jeffrey S Weber; Hoa Nguyen; Peter Cheverton; Daniel Chen; Amy C Peterson; William E Carson; Steven J O'Day Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: P B Chapman; L H Einhorn; M L Meyers; S Saxman; A N Destro; K S Panageas; C B Begg; S S Agarwala; L M Schuchter; M S Ernstoff; A N Houghton; J M Kirkwood Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Thomas E Stinchcombe; Mark A Socinski; Christine M Walko; Bert H O'Neil; Frances A Collichio; Anastasia Ivanova; Hua Mu; Michael J Hawkins; Richard M Goldberg; Celeste Lindley; E Claire Dees Journal: Cancer Chemother Pharmacol Date: 2007-02-07 Impact factor: 3.333
Authors: Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic Journal: Cancer Date: 2009-01-01 Impact factor: 6.860
Authors: Evan M Hersh; Steven J O'Day; Antoni Ribas; Wolfram E Samlowski; Michael S Gordon; Deganit E Shechter; Alicia A Clawson; Rene Gonzalez Journal: Cancer Date: 2010-01-01 Impact factor: 6.860
Authors: Axel Hauschild; Sanjiv S Agarwala; Uwe Trefzer; David Hogg; Caroline Robert; Peter Hersey; Alexander Eggermont; Stephan Grabbe; Rene Gonzalez; Jens Gille; Christian Peschel; Dirk Schadendorf; Claus Garbe; Steven O'Day; Adil Daud; J Michael White; Chenghua Xia; Kiran Patel; John M Kirkwood; Ulrich Keilholz Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Enrique Espinosa; Alfonso Berrocal; José Antonio López Martín; María González Cao; Pablo Cerezuela; José Ignacio Mayordomo; Salvador Martín Algarra Journal: Clin Transl Oncol Date: 2012-05 Impact factor: 3.405
Authors: Elizabeth Ann L Enninga; Wendy K Nevala; Shernan G Holtan; Alexey A Leontovich; Svetomir N Markovic Journal: Melanoma Res Date: 2016-10 Impact factor: 3.599
Authors: Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman Journal: Am J Clin Dermatol Date: 2013-06 Impact factor: 7.403
Authors: Apostolia M Tsimberidou; Yang Ye; Jennifer Wheler; Aung Naing; David Hong; Uchechi Nwosu; Kenneth R Hess; Robert A Wolff Journal: Cancer Chemother Pharmacol Date: 2013-02-03 Impact factor: 3.333